Welcome to our dedicated page for Amphastar Pharma news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharma stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a biopharmaceutical company focused on technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API products. The AMPH news feed on Stock Titan brings together the company’s press releases and market-moving updates so readers can follow how its product portfolio, licensing deals, and financial performance evolve over time.
News about Amphastar often centers on regulatory milestones and pipeline progress. The company has reported U.S. Food and Drug Administration approval of its ANDA for Iron Sucrose Injection, USP, a generic iron sucrose injection indicated for iron deficiency anemia in chronic kidney disease. It also issues updates on its ANDAs, biosimilar insulin candidate, and proprietary peptide and protein products, including licensed peptide assets targeting oncology and ophthalmology.
Another recurring theme in AMPH news is strategic licensing and research agreements. Amphastar has announced exclusive license agreements with Nanjing Anji Biotechnology Co., Ltd. and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for proprietary peptide products and for AMP-110, a fully synthetic ACTH analog in early-phase human clinical development. The company also discloses contract research agreements for recombinant peptide research cell banks supporting its pipeline.
Investors can also track quarterly earnings releases, non-GAAP financial metrics, and share repurchase authorizations, as well as announcements about expanded manufacturing capacity and distribution partnerships, such as the exclusive distribution of BAQSIMI® in parts of the Greater China region. By following AMPH news, readers gain insight into Amphastar’s mix of complex generics, proprietary medicines, manufacturing footprint, and related-party agreements that shape its long-term business profile.
Amphastar Pharmaceuticals reported net revenues of $171.8 million for the three months ended March 31, 2024. The company achieved GAAP net income of $43.2 million and adjusted non-GAAP net income of $55.3 million. Notable highlights include BAQSIMI revenue growth of 22% over the first quarter of 2023. The company experienced positive sales increases in several key products like Glucagon, Epinephrine, and Primatene MIST ®. However, there were decreases in sales of Lidocaine, Enoxaparin, and Naloxone. The company's gross profit margin was 52.4% of net revenues, driven by factors like increased sales of higher-margin products. Amphastar's financial performance demonstrates a strong first quarter with promising growth potential.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will release its first quarter earnings for 2024 on May 8, 2024. The company focuses on developing, manufacturing, and selling generic and proprietary injectable, inhalation, and intranasal products. They also sell insulin API products primarily used in hospital settings. The conference call to discuss financial results will be held at 2:00 p.m. Pacific Time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.